Effective combination therapy for diabetes mellitus type 2
AbstractTreatment of diabetes mellitus type 2 is a complex task. Monotherapy with oral hypoglycemic agents are not always achieves adequate glycemic control, and therefore the need to transition to a combination therapy of diabetes. The use of two or more medications significantly reduces patient compliance, so the use of a fixed combination of two pathogenetically targeted drugs – metformin and glibenclamide in one tablet (Glibomet®) contributes not only to the achievement of the target parameters of glycemic control and the prevention of macrovascular complications, but also allows you to make patient care more cost-effective.
Keywords:diabetes mellitus type 2, combination therapy, metformin, glibenclamide, fixed combination
Endocrinology: News, Opinions, Training. 2014; (3): 11–23.